Marinus Pharmaceuticals (MRNS) is a clinical-stage biopharmaceutical company. The company’s clinical-stage product candidate, ganaxalone, is a modulator of the GABAA receptor. The GABAA receptor is a target in the brain associated with anti-seizure, anti-depression, and anti-anxiety effects.
Ganaxalone is being developed as intravenous, oral capsule, and oral liquid formulations. With this drug, the company aims to increase the reach of the therapy in both adult and pediatric segments across acute and chronic care settings. The availability of multiple formulations of the drug will also allow its use in both inpatient and self-administered settings.
Analysts’ ratings for Marinus Pharmaceuticals
Both of the analysts covering Marinus Pharmaceuticals in December 2017 have given the company a “buy” rating. The mean rating for the stock is two with a mean target price of $22.
Of the 14 analysts covering Sage Therapeutics (SAGE) in December 2017, 13 analysts have given the company a “buy” or higher rating, and one analyst has given the stock a “hold” rating. The mean rating for the stock is 1.64 with a target price of $202. For Zogenix (ZGNX), all the six analysts covering the company in December 2017 have given it a “buy” or a higher rating. The mean rating for the stock is 1.5 with a target price of $50. Meanwhile, of the five analysts covering Zynerba Pharmaceuticals (ZYNE), three analysts have given it a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for the stock is two with a target price of $15.
In the next part of the series, we’ll take a look at ganaxalone, Marinus Pharmaceuticals’ lead product candidate.